{"entity":{"id":"e1910","kind":"trial","name":"ECOG-ACRIN E1910","aka":[],"tldr":"Proved that adding the immunotherapy blinatumomab to standard treatment saves lives even in patients whose leukaemia was already undetectable.","summary":"224 MRD-negative patients randomised. 3-year OS 85% vs 68% (HR 0.41, 95% CI 0.23-0.73); relapse-free survival 80% vs 64%. NEJM 2024. Basis for the June 2024 FDA approval of blinatumomab in consolidation regardless of MRD status; changed frontline adult ALL worldwide. Benefit persisted across age and MRD sensitivity.","status":"positive","asOf":"2026-09-07","links":[{"label":"ClinicalTrials.gov NCT02003222","url":"https://clinicaltrials.gov/study/NCT02003222"},{"label":"NEJM 2024","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2312948"}],"tags":[],"related":[],"cancers":["all-leukemia","aya-cancers"],"sections":[],"technologies":["t-cell-engager"],"targets":["cd19","cd3"],"drugs":["blinatumomab"],"companies":["ecog-acrin"],"institutions":[],"pathways":[],"terms":["mrd-negative-cr"],"trials":[],"people":["mark-litzow"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02003222","phase":"3","setting":"Newly diagnosed Ph-negative B-ALL, age 30-70, in MRD-negative remission after induction: blinatumomab added to consolidation chemotherapy vs chemotherapy alone","sponsor":"ECOG-ACRIN / NCI","result":"3-year OS 85% vs 68%; HR 0.41.","started":"2014-05-19","startedType":"actual","yearReported":2024,"enrolled":488,"enrolledBasis":"registry","outcomes":[{"endpoint":"Overall survival at 3 years (MRD-negative cohort)","primary":true,"unit":"%","arms":[{"name":"Blinatumomab + chemotherapy","n":112,"value":85},{"name":"Chemotherapy","n":112,"value":68}],"hr":0.41,"ci":[0.23,0.73],"p":"0.002","source":"https://www.nejm.org/doi/full/10.1056/NEJMoa2312948"},{"endpoint":"Relapse-free survival at 3 years","unit":"%","arms":[{"name":"Blinatumomab + chemotherapy","value":80},{"name":"Chemotherapy","value":64}],"source":"https://doi.org/10.1056/NEJMoa2312948"}],"replication":"GMALL 08/2013 and the paediatric AALL1731 trial independently show blinatumomab improving outcomes when added to frontline therapy, in different age groups and risk strata."},"route":"/trials/e1910/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"aya-cancers","kind":"cancer","name":"Adolescent and young adult cancers (ages 15 to 39)","route":"/cancers/aya-cancers/"},{"id":"all-paediatric-high-risk","kind":"cancer","name":"High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL)","route":"/cancers/all-paediatric-high-risk/"},{"id":"all-paediatric-standard-risk","kind":"cancer","name":"Standard-risk B-cell acute lymphoblastic leukaemia in children","route":"/cancers/all-paediatric-standard-risk/"}],"technology":[{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"},{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"}],"drug":[{"id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/"}],"company":[{"id":"ecog-acrin","kind":"company","name":"ECOG-ACRIN Cancer Research Group","route":"/companies/ecog-acrin/"}],"term":[{"id":"mrd-negative-cr","kind":"term","name":"MRD-negative complete remission","route":"/terms/mrd-negative-cr/"}],"person":[{"id":"mark-litzow","kind":"person","name":"Mark R. Litzow","route":"/people/mark-litzow/"}],"pairing":[{"id":"blinatumomab-frontline-consolidation","kind":"pairing","name":"Blinatumomab added to frontline chemotherapy","route":"/pairings/blinatumomab-frontline-consolidation/"}],"paper":[{"id":"paper-e1910-blinatumomab-mrd-negative-all-nejm-2024","kind":"paper","name":"ECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission","route":"/key-papers/paper-e1910-blinatumomab-mrd-negative-all-nejm-2024/"}]}}